Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

TerminatedOBSERVATIONAL
Enrollment

83

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Non-Small Cell Lung Cancer
Interventions
OTHER

None (Observational Study)

Not applicable since Observational Study

Trial Locations (23)

11590

Research Site, Westbury

11967

Research Site, Shirley

17403

Research Site, York

33014

Research Site, Miami Lakes

44646

Research Site, Massillon

44708

Research Site, Canton

44710

Research Site, Canton

45219

Research Site, Cincinnati

48098

Research Site, Troy

60076

Research Site, Skokie

70433

Research Site, Covington

75246

Research Site, Dallas

75601

Research Site, Longview

77024

Research Site, Houston

78745

Research Site, Austin

79902

Research Site, Odessa

80204

Research Site, Denver

80222

Research Site, Golden

90027

Research Site, Los Angeles

90033

Research Site, Los Angeles

50010-3014

Research Site, Ames

07932

Research Site, Florham Park

08056

Research Site, Mickleton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06192004 - Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD | Biotech Hunter | Biotech Hunter